CO091 | DOWNREGULATION OF MARKERS OF PLATELET ACTIVATION, PLATELET TURNOVER, AND PLATELET DESIALYLATION IN GOOD RESPONDERS TO FIRST-LINE TREATMENT(S) FOR IMMUNE THROMBOCYTOPENIA
Abstract
Background and Aims. In immune thrombocytopenia (ITP), thrombocytopenia is the result of immune-mediated accelerated platelet clearance and impaired megakaryopoiesis. Evidence suggests that the pathogenic mechanisms of ITP may be heterogeneous across patients and modulated by treatment. Flow cytometry (FC) platelet profiling may help identify residual pathogenic pathways and support mechanism-based treatment tailoring. With this study, we aimed to investigate FC platelet markers in recipients of first-line ITP treatment(s). Methods. We included adult ITP patients followed up at the Haematology outpatient clinic of Hospital San Paolo, Milan, sampled before and after ITP-specific first-line treatment (high-dose corticosteroids and/or intravenous immunoglobulin, IVIG), administered as per current clinical guidelines. Post-treatment samples were obtained at least 14 days after the start of corticosteroids and 3 days after the start of IVIG. For this analysis, patients were classified as good responders, responders, and poor responders based on their post-treatment platelet counts (≥100x109/L, 50-99x10/L, and ≤49x10/L, respectively). We evaluated markers of circulating activated platelets [surface p-selectin expression, platelet-monocyte and platelet-granulocyte aggregates (PMAs, PGAs)], platelet turnover (reticulated platelets), and platelet desialylation (platelet β-galactose exposure) through FC. The cut-off was the 95th centile of 20 healthy subjects. This project was funded by the Italian Ministry of Health (SG-2021-12375578). Results. Thirty-two patients were enrolled in this study (20 females). All patients had been treated with ITP-directed first-line treatment(s). Based on their post-treatment platelet counts, 14 patients were classified as good responders, 8 as responders, and 10 as poor responders. With regard to markers of circulating activated platelets, the highest proportion of patients with p-selectin-positive platelets was found in the poor response group (5/10, 50%) compared to the response (2/8, 25%) and good response (0/13, 0%) groups (poor responders vs. good responders, p=0.01). Similar trends were observed for PMAs [6/10 (60%), 3/8 (38%), and 3/13 (23%)], PGAs [7/10 (70%), 3/8 (38%), and 5/13 (38%)], increased reticulated platelets [3/10 (30%), 2/8 (25%), and 0/13 (0%)], and platelet desialylation [2/7 (29%), 1/6 (17%), and 1/11 (9%)] in poor responders, responders, and good responders, respectively. Ten patients had samples drawn before and after treatment, all with post-treatment platelet counts ≥50x109/L. The proportions of patients with increased reticulated platelets [pre- vs post-treatment: 4/9 (44%) vs 0/10 (0%), p=0.03], p-selectin positive platelets [3/7 (43%) vs 0/9 (0%), p=0.06], PGAs [8/10 (80%) vs 4/9 (44%), p=0.17], PMAs [9/10 (90%) vs 2/9 (22%), p=0.01], and platelet desialylation [5/8 (63%) vs 1/9 (11%), p=0.05] declined post-treatment. Conclusions. In the examined cohort, there was an overall trend towards the improvement of FC markers of platelet turnover, activation, and desialylation in good responders to ITP-directed first-line treatment, suggesting that the successful downregulation of ITP pathogenic mechanisms may be measurable. Persistent abnormalities in these markers may help identify residual mechanisms of thrombocytopenia and guide personalized treatment escalation in ITP.
Related
- OSW-1 impairs autophagic flux via AMPK/mTORC1/TFEB-dependent TFEB activation and STX17 downregulation, leading to necroptosis in colorectal cancer
- Multimodal assessment of exceptional responders refines subtyping-directed precision treatment in HR+/HER2– breast cancer
- Latexin deletion in the bone marrow niche suppresses leukemia via LIFR downregulation and immune activation
- MHC-I downregulation is associated with immune-evasion in breast cancers with heterogeneous activation of epithelial-mesenchymal plasticity
- Serum miRNA expression profile in responders to acupuncture treatment for diminished ovarian reserve: a study protocol for a nested case-control study.
BibTeX
@article{clerici2026co091,
title = {{CO091 | DOWNREGULATION OF MARKERS OF PLATELET ACTIVATION, PLATELET TURNOVER, AND PLATELET DESIALYLATION IN GOOD RESPONDERS TO FIRST-LINE TREATMENT(S) FOR IMMUNE THROMBOCYTOPENIA}},
author = {Bianca Clerici},
journal = {Bleeding, Thrombosis and Vascular Biology},
year = {2026},
month = oct,
url = {https://www.btvb.org/btvb/article/view/793},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - CO091 | DOWNREGULATION OF MARKERS OF PLATELET ACTIVATION, PLATELET TURNOVER, AND PLATELET DESIALYLATION IN GOOD RESPONDERS TO FIRST-LINE TREATMENT(S) FOR IMMUNE THROMBOCYTOPENIA
AU - Bianca Clerici
PY - 2026
DA - 2026/10/26
JO - Bleeding, Thrombosis and Vascular Biology
UR - https://www.btvb.org/btvb/article/view/793
AB - Background and Aims. In immune thrombocytopenia (ITP), thrombocytopenia is the result of immune-mediated accelerated platelet clearance and impaired megakaryopoiesis. Evidence suggests that the pathogenic mechanisms of ITP may be heterogeneous across patients and modulated by treatment. Flow cytometry (FC) platelet profiling may help identify residual pathogenic pathways and support mechanism-based treatment tailoring. With this study, we aimed to investigate FC platelet markers in recipients of first-line ITP treatment(s). Methods. We included adult ITP patients followed up at the Haematology outpatient clinic of Hospital San Paolo, Milan, sampled before and after ITP-specific first-line treatment (high-dose corticosteroids and/or intravenous immunoglobulin, IVIG), administered as per current clinical guidelines. Post-treatment samples were obtained at least 14 days after the start of corticosteroids and 3 days after the start of IVIG. For this analysis, patients were classified as good responders, responders, and poor responders based on their post-treatment platelet counts (≥100x109/L, 50-99x10/L, and ≤49x10/L, respectively). We evaluated markers of circulating activated platelets [surface p-selectin expression, platelet-monocyte and platelet-granulocyte aggregates (PMAs, PGAs)], platelet turnover (reticulated platelets), and platelet desialylation (platelet β-galactose exposure) through FC. The cut-off was the 95th centile of 20 healthy subjects. This project was funded by the Italian Ministry of Health (SG-2021-12375578). Results. Thirty-two patients were enrolled in this study (20 females). All patients had been treated with ITP-directed first-line treatment(s). Based on their post-treatment platelet counts, 14 patients were classified as good responders, 8 as responders, and 10 as poor responders. With regard to markers of circulating activated platelets, the highest proportion of patients with p-selectin-positive platelets was found in the poor response group (5/10, 50%) compared to the response (2/8, 25%) and good response (0/13, 0%) groups (poor responders vs. good responders, p=0.01). Similar trends were observed for PMAs [6/10 (60%), 3/8 (38%), and 3/13 (23%)], PGAs [7/10 (70%), 3/8 (38%), and 5/13 (38%)], increased reticulated platelets [3/10 (30%), 2/8 (25%), and 0/13 (0%)], and platelet desialylation [2/7 (29%), 1/6 (17%), and 1/11 (9%)] in poor responders, responders, and good responders, respectively. Ten patients had samples drawn before and after treatment, all with post-treatment platelet counts ≥50x109/L. The proportions of patients with increased reticulated platelets [pre- vs post-treatment: 4/9 (44%) vs 0/10 (0%), p=0.03], p-selectin positive platelets [3/7 (43%) vs 0/9 (0%), p=0.06], PGAs [8/10 (80%) vs 4/9 (44%), p=0.17], PMAs [9/10 (90%) vs 2/9 (22%), p=0.01], and platelet desialylation [5/8 (63%) vs 1/9 (11%), p=0.05] declined post-treatment. Conclusions. In the examined cohort, there was an overall trend towards the improvement of FC markers of platelet turnover, activation, and desialylation in good responders to ITP-directed first-line treatment, suggesting that the successful downregulation of ITP pathogenic mechanisms may be measurable. Persistent abnormalities in these markers may help identify residual mechanisms of thrombocytopenia and guide personalized treatment escalation in ITP.
SN - 2785-5309
ER -